Clinical Trial Update: Resistance to the Tyrosine Kinase Inhibitor Osimertinib and Pharmacokinetics in Non-small Cell Lung Cancer

View source ↗

Summary

This clinical trial update investigates resistance to the EGFR inhibitor osimertinib and its pharmacokinetics in non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: Rennes University Hospital | Conditions: Lung Cancer | Status: ACTIVE_NOT_RECRUITING